HC Wainwright Forecasts Mural Oncology Q1 Earnings

Mural Oncology plc (NASDAQ:MURA) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Mural Oncology in a research report issued on Wednesday, March 26th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.81) for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($3.32) EPS.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter in the previous year, the firm posted ($3.57) earnings per share.

A number of other analysts have also weighed in on the stock. Raymond James lowered shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective for the company. in a research note on Tuesday. Jones Trading reaffirmed a “hold” rating on shares of Mural Oncology in a research report on Tuesday. Finally, Morgan Stanley lowered shares of Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Trading Up 1.5 %

MURA opened at $1.35 on Friday. The company has a market capitalization of $23.26 million, a price-to-earnings ratio of -0.15 and a beta of 3.66. Mural Oncology has a 12-month low of $1.28 and a 12-month high of $5.12. The business’s fifty day simple moving average is $3.77 and its 200-day simple moving average is $3.58.

Institutional Trading of Mural Oncology

Several hedge funds have recently modified their holdings of the company. Acorn Capital Advisors LLC bought a new position in shares of Mural Oncology during the 4th quarter worth approximately $4,141,000. Point72 Asset Management L.P. acquired a new position in shares of Mural Oncology during the third quarter worth $340,000. Raymond James Financial Inc. purchased a new stake in shares of Mural Oncology during the 4th quarter valued at $181,000. Virtu Financial LLC acquired a new stake in shares of Mural Oncology in the 4th quarter worth $129,000. Finally, Renaissance Technologies LLC grew its stake in Mural Oncology by 17.4% during the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock worth $768,000 after buying an additional 35,403 shares during the last quarter. 80.21% of the stock is owned by hedge funds and other institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.